In this report, the Global Glycated Hemoglobin Testing Market has been segmented by Product Type, Test Type, Technique, End Users and Geography.

Global Glycated Hemoglobin Testing Market, Segmentation by Product Type

The Global Glycated Hemoglobin Testing Market has been segmented by Product Type into Laboratory HbA1c Testing Products, and Point of Care (POC) HbA1c Testing Products.

Laboratory-based HbA1c testing continues to serve as the gold standard for the diagnosis and management of diabetes. These tests are typically performed in centralized laboratories utilizing advanced techniques such as High-Performance Liquid Chromatography (HPLC). In 2022, the global laboratory HbA1c testing market accounted for approximately 5.8% of the total market, with projections indicating it could grow to 9.5% by 2031, driven by an estimated CAGR of 5.7%. This growth reflects the increasing demand for precise diagnostic solutions to address the rising global incidence of diabetes.

POC HbA1c testing products provide immediate results in a variety of settings, including clinics, pharmacies, and even for home testing. In 2023, the global POC HbA1c testing market was valued at approximately 842.91 million USD and is expected to reach 2,438.57 million USD by 2033, growing at a CAGR of 10.96%. The strong growth of this segment is propelled by the need for rapid diagnostics, especially in remote and resource-limited regions, and the global trend towards decentralized healthcare models.

Global Glycated Hemoglobin Testing Market, Segmentation by Test Type

The Global Glycated Hemoglobin Testing Market has been segmented by Test Type into Laboratory Based Test and Point of Care Test.

Laboratory-based HbA1c tests are considered the gold standard for diagnosing and monitoring diabetes, offering high accuracy and reliability. These tests are typically conducted in centralized laboratories using advanced techniques such as High-Performance Liquid Chromatography (HPLC). In 2023, laboratory-based tests accounted for approximately 70% of the global HbA1c testing market. The segment is projected to grow at a CAGR of 6.7% from 2019 to 2033, driven by the increasing prevalence of diabetes and the demand for precise diagnostic tools.

Point of Care (POC) HbA1c testing offers rapid and convenient results, facilitating immediate clinical decisions in various settings, including clinics, pharmacies, and home care. The POC HbA1c testing market was valued at approximately USD 842.91 million in 2023 and is expected to reach USD 2,438.57 million by 2033, growing at a CAGR of 10.96%. This significant growth is attributed to the rising demand for quick diagnostics, especially in remote and resource-limited areas, and the increasing adoption of decentralized healthcare models.

Global Glycated Hemoglobin Testing Market, Segmentation by End Users

The Global Glycated Hemoglobin Testing Market has been segmented by End Users into Hospitals, Diagnostic Centers, Academic and Research Institutes, and Others.

Hospitals

Hospitals command nearly 50% of the global glycated hemoglobin testing market, driven by the critical need for accurate and timely HbA1c testing in diabetes care. These facilities provide comprehensive diagnostic services, ensuring patients receive precise glucose control assessments for effective diabetes management.

Diagnostic Centers

Diagnostic centers account for approximately 30% of the market, offering accessible and efficient HbA1c testing services to patients. Their reliable testing capabilities support regular monitoring and early detection of diabetic conditions, contributing to better health outcomes.

Academic and Research Institutes

Academic and research institutes hold about 15% of the global glycated hemoglobin testing market. These institutions play a vital role in advancing scientific understanding of diabetes and developing innovative testing methodologies to improve disease management.

Others

The "Others" category makes up around 5% of the market, comprising small clinics and independent laboratories. These providers offer HbA1c testing as part of routine health checks and diabetes management services, enhancing community access to essential diagnostics.

Global Glycated Hemoglobin Testing Market, Segmentation by Technique

The Global Glycated Hemoglobin Testing Market has been segmented by Technique into Chromatography, Immunoassay, Other Technology.

Chromatography

Chromatography represents approximately 60% of the global glycated hemoglobin testing market, renowned for its precision and reliability in measuring HbA1c levels. This method is a cornerstone in diabetes diagnostics, offering high accuracy in long-term glucose monitoring and disease management.

Immunoassay

Immunoassay technology holds close to 30% of the market share, offering a fast and affordable solution for HbA1c detection. Its adaptability makes it suitable for a range of settings, from centralized laboratories to point-of-care environments, supporting regular diabetes management.

Other Technology

Other technologies, including enzymatic assays and boronate affinity methods, account for roughly 10% of the market. These emerging technologies offer varied approaches to HbA1c testing, providing alternatives that balance specificity, ease of use, and cost for diverse diagnostic needs.

Global Glycated Hemoglobin Testing Market, Segmentation by Geography

In this report, the Global Glycated Hemoglobin Testing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Glycated Hemoglobin Testing Market Share (%), by Geographical Region, 2024

North America

North America captures about 38% of the global glycated hemoglobin testing market, fueled by a high diabetes burden, advanced healthcare systems, and rising awareness of diabetes care. The region’s robust infrastructure supports widespread adoption of advanced diagnostic tools for effective diabetes management.

Europe

Europe represents nearly 27% of the market, driven by supportive healthcare regulations, a significant diabetes population, and proactive approaches to early disease detection and monitoring. The increasing focus on comprehensive diabetes care bolsters market growth in this region.

Asia Pacific

Asia Pacific holds close to 23% of the global market, with growth driven by rising diabetes prevalence, expanding healthcare infrastructure, and greater investment in medical technologies. This region is experiencing rapid market expansion due to increased demand for accurate and affordable testing solutions.

Middle East and Africa

The Middle East and Africa contribute around 7% to the global market, supported by increasing healthcare investments and heightened awareness of diabetes control. Despite these gains, adoption remains comparatively limited due to infrastructural and economic challenges.

Latin America

Latin America represents approximately 5% of the glycated hemoglobin testing market, with growth propelled by rising diabetes cases and improved access to diagnostic services. The market is steadily expanding as healthcare systems enhance their diabetes management capabilities.